ReviewDrugs2008
Ramelteon: a review of its use in insomnia.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 61 citations in OpenAlex.
- Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems.Journal of assisted reproduction and genetics · 2011Trial
- Dual orexin receptor antagonists as promising therapeutics for Alzheimer's disease.Npj biological timing and sleep · 2025Review
- An unidentified yet notable modification onFASEB bioAdvances · 2024Article
- The MT1 receptor as the target of ramelteon neuroprotection in ischemic stroke.Journal of pineal research · 2024Article
- Ameliorating effects of ramelteon on oxidative stress, inflammation, apoptosis, and autophagy markers in methotrexate-induced cerebral toxicity.Iranian journal of basic medical sciences · 2022Article
- Concise Six-Step Asymmetric Approach to Ramelteon from an Acetophenone Derivative Using Ir, Rh, Cu, and Ni Catalysis.The Journal of organic chemistry · 2022Article
- Ramelteon, as a Melatonin Agonist, is Expected to be Effective on COVID-19 Induced Organ Damage: The Hypothetic Role of NF-κB Signaling Pathway.Advanced biomedical research · 2022Article
- G-protein coupled receptors and synaptic plasticity in sleep deprivation.World journal of psychiatry · 2021Review
- Melatonin-A Potent Therapeutic for Stroke and Stroke-Related Dementia.Antioxidants (Basel, Switzerland) · 2020Review
- Review
- Pharmacological Treatment of Insomnia.P & T : a peer-reviewed journal for formulary management · 2015Article
- Melatonin and melatonin agonist for delirium in the elderly patients.American journal of Alzheimer's disease and other dementias · 2015Review
- Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers.Contemporary oncology (Poznan, Poland) · 2015Article
- Melatonin-based therapeutics for neuroprotection in stroke.International journal of molecular sciences · 2013Review
- Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands.Molecules (Basel, Switzerland) · 2012Article
- Biological rhythms and mood disorders.Dialogues in clinical neuroscience · 2012Review
- The management of sleep and circadian disturbance in patients with dementia.Current neurology and neuroscience reports · 2012Review
- Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.Aging and disease · 2012Article
- Critical appraisal of ramelteon in the treatment of insomnia.Nature and science of sleep · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ramelteon (Rozerem) is the first melatonin receptor agonist to be approved for the treatment of insomnia; it is not classified as a controlled substance. In patients with chronic insomnia, objectively assessed latency to persistent sleep (LPS) at week 1 was improved with oral ramelteon 8 mg administered 30 minutes before bedtime, compared with placebo, and this effect was maintained throughout the duration of 5-week and 6-month clinical studies. Subjectively assessed sleep latency (sSL) improved in some, but not all, studies. When a statistically significant improvement in sSL occurred at week 1, the effect was maintained throughout the duration of the 5-week studies, but not at all timepoints throughout a 6-month study. Improvements in objectively assessed total sleep time (TST) and sleep efficiency (SE) were only reported during the first week of treatment. Improvements in other objective or subjective measures of sleep were not consistent. Ramelteon was generally well tolerated, did not impair next-day cognitive or motor performance and was not associated with withdrawal symptoms, rebound insomnia or abuse potential. Thus, ramelteon provides a well tolerated option for the treatment of patients with insomnia characterized by difficulty in sleep onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.